Scholarlink

Antibody-drug conjugatesAntibody drug conjugates (ADCs) (ADCs) have become a powerful class of therapeutics in oncology. Since the first approval of Mylotarg®Mylotarg® (gemtuzumab ozogamicinGemtuzumab ozogamicin (GO)) by the US Food and Drug Administration (FDA)Food and Drug Administration (FDA) in 2000, the field has grown rapidly with 11 current FDA-approved ADCs. In 2023, the ADC market had exceeded original projections with a valuation at USD 7.2 billion (Bretz, Antibody drug conjugates market poised for unprecedented growth through 2032, 2024). By 2032, the sales of ADCs are expected to exceed USD 34 billion, with a compound annual growth rate (CAGR) of 17.5%. As of October 2023, there are over 500 active clinical trialsClinical trials involving approved and new ADCs (Udofa, Bioeng Transl Med 9: e10677, 2024), increasing diversity in many areas such as the disease indications, drug payloadsPayloads, and linkersLinkers. In this chapter, the main components of ADCs will be reviewed with a focus on the currently approved ADCs, along with a discussion of future directions based on examination of active clinical trialsClinical trials.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Summary and Future Directions of Antibody-Drug Conjugates

  • 章节

  • 发表日期：

    2025年

查看全文
  • Jennica L. Zaro,
  • Jeffery Wang,
  • Wei-Chiang Shen

摘要

Antibody-drug conjugatesAntibody drug conjugates (ADCs) (ADCs) have become a powerful class of therapeutics in oncology. Since the first approval of Mylotarg®Mylotarg® (gemtuzumab ozogamicinGemtuzumab ozogamicin (GO)) by the US Food and Drug Administration (FDA)Food and Drug Administration (FDA) in 2000, the field has grown rapidly with 11 current FDA-approved ADCs. In 2023, the ADC market had exceeded original projections with a valuation at USD 7.2 billion (Bretz, Antibody drug conjugates market poised for unprecedented growth through 2032, 2024). By 2032, the sales of ADCs are expected to exceed USD 34 billion, with a compound annual growth rate (CAGR) of 17.5%. As of October 2023, there are over 500 active clinical trialsClinical trials involving approved and new ADCs (Udofa, Bioeng Transl Med 9: e10677, 2024), increasing diversity in many areas such as the disease indications, drug payloadsPayloads, and linkersLinkers. In this chapter, the main components of ADCs will be reviewed with a focus on the currently approved ADCs, along with a discussion of future directions based on examination of active clinical trialsClinical trials.